First Tracks Biotherapeutics Inc
NASDAQ:TRAXBiotechnology
Healthcare
$44.50 -4.87%
-$0.89 today
- Market cap
- $1.87B
- Beta
- 0.00
- P/E (TTM)
- -6.1
- EPS (TTM)
- -$2.81
52W Low $14.72High $26.80
Volume 0.75M
Average 0.43M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$179.01M
FY 2025 · Annual
Net Income
-$166.09M
FY 2025 · Annual
Income Statement
USD
Metric | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|
| Revenue | 0 | 0 | 0 |
| Cost of Revenue | 0 | 152.35M | 139.61M |
| Gross Profit | 0 | (152.35M) | (139.61M) |
| Gross Margin | — | — | — |
| Research & Development | 97.59M | 152.35M | 139.61M |
| Selling, General & Admin | 20.87M | 28.76M | 39.39M |
| Operating Expenses | 118.46M | 28.76M | 39.39M |
| Depreciation & Amortization | 2.38M | 2.4M | 559K |
| EBITDA | (116.09M) | (178.7M) | (178.45M) |
| EBITDA Margin | — | — | — |
| Operating Income | (118.46M) | (181.1M) | (179.01M) |
| Operating Margin | — | — | — |
| Interest Income | 12.31M | 17.38M | 0 |
| Interest Expense | 0 | 0 | 0 |
| Other Income / Expenses | 12.31M | 17.4M | 12.92M |
| Income Before Tax | (106.15M) | (163.71M) | (166.09M) |
| Pre-Tax Margin | — | — | — |
| Income Tax Expense | 0 | 0 | 0 |
| Net Income | (106.15M) | (163.71M) | (166.09M) |
| Net Margin | — | — | — |
| EPS (Basic) | (3.05) | 0.00 | 0.00 |
| EPS (Diluted) | (3.05) | 0.00 | 0.00 |
| 34.75M | 0 | 0 | |
| 34.75M | 0 | 0 |
TRAX Earnings Waterfall · TTM
NASDAQ:TRAX · Revenue to Net Income
No earnings data available.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G | SC 13G filing | Nov 12, 2026 | |
| SC 13G/A | SC 13G/A filing | Nov 6, 2026 | |
| 424B3 | 424B3 filing | Nov 4, 2026 | |
| 424B3 | 424B3 filing | Nov 4, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 3, 2026 |
How much revenue does TRAX generate?
First Tracks Biotherapeutics Inc (TRAX) reported $0.00 of revenue in fiscal 2025.
Is TRAX profitable?
First Tracks Biotherapeutics Inc (TRAX) reported -$166.09M of net income.
Continue the stock analysis
Jump to another research area for this company.